Shorts Target VIVUS (VVUS) Following January Pop; May be Entering 'Oversold' Territory
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 14% on Q1 earnings beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
VIVUS (VVUS) Qsymia Prescriptions Jump 140%+ After Free Trial Program Starts
January 7, 2013 6:45 AM ESTVIVUS, Inc. (Nasdaq: VVUS) shares are looking to open higher Monday amid new Qsymia prescription data.
According to Bloomberg, Qsymia prescriptions jumped about 140 percent higher from 5,394 for the four-weeks ended October 26th to 12,978 in the four-week period ended December 21st. The pop came following commencement of its Free Trial program on November 19th through two certified pharmacies.
VIVUS said that a third pharma started the program in late December.
The October data was revised higher from an initial estimate of 4,904 prescriptions.
More color from an 8-K filing made... More
